Rubric Capital Management LP Sells 216,825 Shares of Collegium Pharmaceutical, Inc. $COLL

Rubric Capital Management LP lessened its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 14.5% in the first quarter, Holdings Channel reports. The institutional investor owned 1,279,611 shares of the specialty pharmaceutical company’s stock after selling 216,825 shares during the quarter. Rubric Capital Management LP’s holdings in Collegium Pharmaceutical were worth $42,317,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in Collegium Pharmaceutical by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 2,256,254 shares of the specialty pharmaceutical company’s stock worth $104,465,000 after acquiring an additional 29,876 shares during the period. Renaissance Technologies LLC raised its position in shares of Collegium Pharmaceutical by 1.1% in the fourth quarter. Renaissance Technologies LLC now owns 1,617,349 shares of the specialty pharmaceutical company’s stock worth $74,883,000 after buying an additional 18,160 shares in the last quarter. Janus Henderson Group PLC grew its position in Collegium Pharmaceutical by 59.1% during the fourth quarter. Janus Henderson Group PLC now owns 1,448,578 shares of the specialty pharmaceutical company’s stock worth $67,026,000 after buying an additional 538,337 shares in the last quarter. Principal Financial Group Inc. grew its position in Collegium Pharmaceutical by 0.3% during the fourth quarter. Principal Financial Group Inc. now owns 1,313,662 shares of the specialty pharmaceutical company’s stock worth $60,823,000 after buying an additional 3,891 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in Collegium Pharmaceutical by 65.3% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,312,655 shares of the specialty pharmaceutical company’s stock worth $60,776,000 after acquiring an additional 518,721 shares during the last quarter.

Wall Street Analysts Forecast Growth

COLL has been the subject of several research analyst reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Collegium Pharmaceutical in a research report on Monday, July 6th. Wall Street Zen lowered shares of Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Saturday. Zacks Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Finally, Truist Financial upgraded shares of Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Collegium Pharmaceutical has a consensus rating of “Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Price Performance

COLL opened at $35.52 on Tuesday. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The stock has a market capitalization of $1.15 billion, a P/E ratio of 17.41 and a beta of 0.73. The stock has a 50-day moving average price of $34.69 and a 200-day moving average price of $37.81. Collegium Pharmaceutical, Inc. has a 12-month low of $29.19 and a 12-month high of $50.79.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. The company had revenue of $193.52 million for the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.Collegium Pharmaceutical’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the firm posted $1.49 EPS. Equities analysts predict that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.